{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:08:13Z","timestamp":1779361693653,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJFS2125"],"award-info":[{"award-number":["JPMJFS2125"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with dementia (PwDs) are particularly vulnerable to adverse events (AEs). Recognising and understanding AEs is essential to improve patient safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study analysed FAERS data from the past decade to identify AE symptom characteristics in PwDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The FAERS data (2014\u20132024) was reviewed, extracting reports with dementia as an indication. The reports\u2019 features were described and analysed, including k-means clustering to identify patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2014 to 2024, 20,913 reports related to PwDs were extracted. Consumers and health care professionals were the most common reporters. Regarding patient outcomes, 38.7% of records reported hospitalisation and 10.6% reported death. The most frequently reported AEs were death, aggression, and bradycardia. Cholinesterase inhibitors (ChEIs), antipsychotics, and anticonvulsants were frequently associated with nervous system and psychiatric disorders. K-means clustering identified four groups, with older PwDs on ChEIs experiencing cardiovascular issues, while younger PwDs on antipsychotics faced higher mortality, drug ineffectiveness, and fall risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Many symptoms observed in PwDs are often attributed to ageing or disease progression, potentially obscuring their link to drug-related causes. Enhancing AE reporting across healthcare roles, promoting public awareness, conducting regular medication reviews, and providing training in early detection are vital for the safe management of dementia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09246479251385395","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:32:45Z","timestamp":1762515165000},"page":"193-200","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-related adverse events in people with dementia \u2013 Statistical data from the FDA adverse event reporting system"],"prefix":"10.1177","volume":"37","author":[{"given":"Jieyu","family":"Mao","sequence":"first","affiliation":[{"name":"The University of Osaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyae","family":"Yamakawa","sequence":"additional","affiliation":[{"name":"The University of Osaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Takeya","sequence":"additional","affiliation":[{"name":"The University of Osaka"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"e_1_3_6_2_2","unstructured":"World Health Organization (WHO). Dementia 2023 [cited 2024 October]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1472932"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16060934"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2022.01.083"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.5455\/msm.2018.30.221-224"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1188\/10.ONF.S1.7-16"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30368-0"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2480"},{"key":"e_1_3_6_10_2","unstructured":"World Health Organization. Patient safety 2023. [cited 2025 March 19]. Available from: https:\/\/www.who.int\/zh\/news-room\/fact-sheets\/detail\/patient-safety"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01397-6"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-021-00481-9"},{"key":"e_1_3_6_13_2","unstructured":"U.S. Food and Drug Administration. Draft guidance for industry: postmarketing safety reporting for human drug and biological products including vaccines 2001. [cited 2025 15 Jul]. Available from: https:\/\/www.fda.gov\/media\/73593\/download"},{"key":"e_1_3_6_14_2","unstructured":"U.S. Food and Drug Administration. Potential signals of serious risks\/new safety information identified from the FDA adverse event reporting system (FAERS). [cited 2025 Jul 8]. Available from: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event-reporting-system (2025)."},{"key":"e_1_3_6_15_2","unstructured":"Administration USFaD. FDA adverse event reporting system (FAERS) n.d. [cited 2025 Jul 8]. Available from: https:\/\/open.fda.gov\/data\/faers\/?utm_source=chatgpt.com"},{"issue":"2","key":"e_1_3_6_16_2","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Hansen RA","year":"2008","unstructured":"Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3(2): 211\u2013225.","journal-title":"Clin Interv Aging"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1533317518775044"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015602274"},{"issue":"6","key":"e_1_3_6_19_2","first-page":"50","article-title":"Beyond the black box: what is the role for antipsychotics in dementia?","volume":"7","author":"Meeks TW","year":"2008","unstructured":"Meeks TW, Jeste DV. Beyond the black box: what is the role for antipsychotics in dementia? Curr Psychiatr 2008; 7(6): 50\u201365.","journal-title":"Curr Psychiatr"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-00992-5"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01109"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-201212"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12912-023-01376-9"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjcn\/zvac113"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1336"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13043-7"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1839-6"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6630404"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e318235b758"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04423.x"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251385395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479251385395","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251385395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:58:38Z","timestamp":1779361118000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479251385395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/09246479251385395"],"URL":"https:\/\/doi.org\/10.1177\/09246479251385395","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/09246479251385395\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251385395\/v1\/review1","asserted-by":"object"}]},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}